Binh Duong, September 03, 2021 –This afternoon, Secretary of the Provincial Party Committee Nguyen Van Loi, Head of Binh Duong Provincial Steering Committee for Covid-19 Prevention and Control, led the provincial delegation to visited and checked the prevention and control of the Covid-19 pandemic at Stellapharm Joint Venture Company Limited - Branch I at VSIP I – Binh Duong.
Secretary of the Provincial Party Committee Nguyen Van Loi and the delegation worked with the Board of Directors of Stellapharm Co., Ltd. on the afternoon of September 3.

Accompanying the delegation were Mr. Mai Hung Dung, Standing Member of the Provincial Party Committee, Standing Vice Chairman of the Provincial People's Committee; Associate Professor - Doctor Nguyen Lan Hieu, Director of Hanoi Medical University Hospital together with leaders of some provincial departments and branches Thuan An city.

At the meeting, Ms. Nguyen Ngoc Lieu, Deputy General Director of Stellapharm, said that Stellapharm is currently coordinating with Optimus Pharmaceutical Company (India) to transfer technology and production materials for Molnupiravir anti-Covid-19 drug. Currently, the production and research process for Molnupiraviris initially going through the clinical trial phase at Thong Nhat Hospital, which is the final stage. It is expected to expand the clinical trial at Pham Ngoc Thach Hospital in the coming days. Since the clinical trial results are available, the company will send a written request to the Ministry of Health to allow the expansion of clinical trials on a large scale of around 30,000 Covid-19 patients.

A Stellapharm worker checks drugs before packaging. 

Mr. Nguyen Van Loi highly appreciated the company’s efforts, which has well performed the production work in safety and prevention. He requested the Management Board of Binh Duong Provincial Industrial Parks and the company Management to coordinate soon to arrange for the employees to access the second dose of Covid-19 vaccine.

In addition, he suggested Stellapharm to consolidate the legal issues and re-evaluate the pharmaceutical formula in official documents from the inventor of Molnupiravir, together with a plan to test drug safety through clinical trials. Manufacturing and supply should accelerate to serve the early treatment of Covid-19 patients.

Source: Binh Duong Newspaper